Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORINYL 1+80 28-DAY vs ALYACEN 7/7/7
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing a progestin (norethindrone) and an estrogen (mestranol). Suppresses gonadotropin (FSH and LH) release via negative feedback, inhibiting ovulation. Also induces changes in cervical mucus and endometrium to impede sperm penetration and implantation.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Prevention of pregnancy,Treatment of moderate acne vulgaris in females ≥15 years who have achieved menarche and are willing to use an oral contraceptive for contraception,Treatment of menstrual disorders (off-label),Emergency contraception (off-label)
Prevention of pregnancy
One tablet (1 mg norethindrone / 80 mcg ethinyl estradiol) orally once daily for 28-day cycle without placebo.
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
Norethindrone: terminal elimination half-life of 5.3-10.5 hours; Mestranol (as ethinyl estradiol): terminal half-life of 7-20 hours. Clinically, steady state is achieved after 5-7 days of daily dosing; the half-life supports once-daily dosing for consistent hormonal levels.
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (Cr Cl 30-50 m L/min).
Norethindrone undergoes hepatic metabolism via reduction and conjugation; major enzyme CYP3A4. Mestranol is rapidly demethylated to ethinyl estradiol, which undergoes hepatic metabolism via CYP3A4 and conjugation.
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation.
Norethindrone is primarily excreted in urine (approximately 60%) and feces (approximately 40%) as glucuronide and sulfate conjugates. Mestranol is metabolized to ethinyl estradiol; ethinyl estradiol and its metabolites are excreted in urine (40%) and feces (60%).
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
Norethindrone: 80-85% bound to albumin and SHBG; Mestranol (as ethinyl estradiol): 95-98% bound to albumin.
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
Norethindrone: Vd ~ 4.0 L/kg, indicating extensive tissue distribution; Mestranol (as ethinyl estradiol): Vd ~ 1.5-2.5 L/kg.
0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity.
Norethindrone: oral bioavailability ~ 64%; Mestranol: rapidly metabolized to ethinyl estradiol, with combined effects providing oral contraceptive efficacy. Both components are administered orally.
Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%.
No dose adjustment required; use with caution in severe renal impairment (GFR <30 m L/min) due to potential fluid retention.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (Cr Cl ≥30 m L/min).
Contraindicated in acute liver disease or decompensated cirrhosis (Child-Pugh class B or C). Use with caution in mild hepatic impairment (Child-Pugh class A) with monitoring.
Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A.
Not indicated for prepubertal females. Postmenarchal adolescents: same adult dosing; adjust if <45 kg with caution.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults.
Not indicated for postmenopausal women due to increased risk of thromboembolism and lack of contraceptive benefit.
Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age (especially >35 years) and with heavy smoking (≥15 cigarettes/day). Women who use combination oral contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
Increased risk of thrombotic and thromboembolic events (e.g., MI, stroke, VTE), especially in smokers >35 years and those with hypertension, diabetes, hyperlipidemia, or obesity. Discontinue if thrombotic event occurs. Hepatic neoplasia risk. Elevated blood pressure. Gallbladder disease. Carbohydrate/lipid effects. Worsening of depression. Fluid retention. Hereditary angioedema. Chloasma. Lens opacities. Discontinue if jaundice develops. Use caution with history of depression, diabetes, or familial hyperlipidemia.
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Cerebrovascular disease,Carcinoma of the breast or reproductive organs,Hepatic adenoma or carcinoma,Ocular lesions (retinal thrombosis, papilledema),Gallbladder disease,Carbohydrate/lipid effects,Elevated blood pressure,Hereditary angioedema,Chloasma,Hepatic impairment
Thrombophlebitis, thromboembolic disorders, cerebral vascular disease, or past history of these conditions. Known or suspected pregnancy. Liver tumor (benign or malignant) or active liver disease. Known or suspected carcinoma of the breast or endometrium. Undiagnosed abnormal genital bleeding. Hypersensitivity to any component. Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, dasabuvir, or glecaprevir/pibrentasvir.
Breast cancer (current or history),Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Current or history of thrombotic disorders (DVT, PE, stroke, MI),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Active liver disease (tumors, hepatitis, cirrhosis),Uncontrolled hypertension,Smoking (if age >35),Hypersensitivity to any component
No specific food restrictions. Grapefruit juice may slightly increase estrogen levels; moderate consumption is acceptable. Consistent dietary habits are recommended to maintain stable hormone levels.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended.
FDA Pregnancy Category X. Contraindicated in pregnancy due to estrogen component (mestranol) and progestin (norethindrone). First trimester: increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second and third trimesters: potential for androgenic effects on female fetus (pseudohermaphroditism), and possible long-term effects from estrogenic activity. Not recommended for use during pregnancy.
ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development.
Mestranol and norethindrone are excreted into breast milk in small amounts. M/P ratio not reported. May reduce milk production and composition (decreased protein and fat content). Potential for adverse effects on the infant (e.g., jaundice, breast enlargement in males). Generally not recommended during breastfeeding; alternative contraception advised.
Contraindicated in breastfeeding. Ethinylestradiol reduces milk quantity and quality. Norethindrone is excreted in low amounts (M/P ratio approximately 0.3-0.4). However, combination oral contraceptives are not recommended during lactation due to estrogen effects on milk production.
Not applicable; drug is contraindicated during pregnancy. No dose adjustments recommended or studied. Pharmacokinetic changes in pregnancy (increased Volume of distribution, altered clearance) are relevant if accidental exposure occurs, but no dose guidance exists. Discontinue immediately upon suspected pregnancy.
ALYACEN 7/7/7 is contraindicated in pregnancy; no dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance of steroids) would theoretically require higher doses, but due to fetal risks, alternative therapies should be used.
Combined hormonal contraceptive containing 1 mg norethindrone and 0.035 mg ethinyl estradiol. 28-day regimen with 21 active pills and 7 placebo pills. For patients with compliance concerns, consider a 24-day active regimen alternative. Not recommended for patients with migraine with aura or smokers over 35. Monitor blood pressure at baseline and annually. Counsel on increased VTE risk, especially in first year of use. Use with caution in patients with uncontrolled hypertension, diabetes with vascular disease, or history of DVT/PE.
ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception.
Take one pill daily at the same time for full contraceptive efficacy.,If you miss a pill, refer to the package insert instructions; use backup contraception if needed.,Common side effects include nausea, breast tenderness, and breakthrough bleeding, usually improving within 3 months.,Do not smoke while taking this medication; smoking increases risk of serious cardiovascular events.,Report sudden severe headache, chest pain, shortness of breath, or leg swelling to your healthcare provider.,This does not protect against HIV or other sexually transmitted infections; use condoms for STI prevention.,Inform your healthcare provider about all medications and supplements, as some may reduce effectiveness.
Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo).,If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended.,Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles.,Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache.,This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs).,Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NORINYL 1+80 28-DAY vs ALYACEN 7/7/7, answered by our medical review team.
NORINYL 1+80 28-DAY is a Oral Contraceptive that works by Combination oral contraceptive containing a progestin (norethindrone) and an estrogen (mestranol). Suppresses gonadotropin (FSH and LH) release via negative feedback, inhibiting ovulation. Also induces changes in cervical mucus and endometrium to impede sperm penetration and implantation.. ALYACEN 7/7/7 is a Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORINYL 1+80 28-DAY and ALYACEN 7/7/7 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORINYL 1+80 28-DAY is: One tablet (1 mg norethindrone / 80 mcg ethinyl estradiol) orally once daily for 28-day cycle without placebo.. The standard adult dose of ALYACEN 7/7/7 is: ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORINYL 1+80 28-DAY and ALYACEN 7/7/7 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORINYL 1+80 28-DAY is classified as Category C. FDA Pregnancy Category X. Contraindicated in pregnancy due to estrogen component (mestranol) and progestin (norethindrone). First trimester: increased risk of congenital anomalies,. ALYACEN 7/7/7 is classified as Category C. ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.